If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A Spanish research group of the public health system has developed a technology based on polymorphisms for diagnosis, prognosis and classification of patients with sensorineural hearing loss, and especially those with Meniere's disease. Until now there has been no available biological method which allows early diagnosis or establishing a long-term hearing loss prognosis.
A license and / or technical cooperation agreement is sought.
Ménière's disease (MS) is a chronic disorder that affects the inner ear characterized by recurrent episodes of vertigo, progressive instability, sound pressure, tinnitus and loss of hearing.
Some research studies have suggested an association between the gene TLR10 and auto immune diseases. On the other hand, the product of the gene TLR10 is an unknown ligand receptor that may play an important role in the autoimmune process and the exon 3 variants of this gene can modulate innate immune response and determine the condition of both ears. Therefore, systematic study by means of a genotyping microarray for genotyping variants previously associated with other autoimmune diseases in 186 loci (immunochip) seems to be a way to explore the maximum number of variants per sample, which improves diagnostic yield.
A wide range of medical and surgical treatments for hearing loss, and specifically for Ménière's disease, has been proposed. All of them have yielded different results with respect to symptom remission and side effects.
Currently available treatments for hearing loss can be extremely aggressive and can put the patient's hearing at risk. It would be important to provide a prognosis marker which will allow evaluating treatment suitability. Until now there has been no available biological method or marker which allows early diagnosis or establishing a long-term hearing loss prognosis which is useful for patient classification and makes it easier to make decisions concerning treatment and disease progression follow-up.
A Spanish hospital research group has developed a technique that uses gene polymorphism for diagnosis, prognosis and classification of patients with sensorineural hearing loss, and especially those with Meniere´s disease.
The researchers demonstrated the association of two allelic variants located in specific genomic coordinates in the NFKB1 gene that determine high risk for early hearing loss in Meniere's disease with unilateral sensorineural hearing loss.The results obtained by using polymorphisms or single nucleotide variants allow obtaining useful information in the diagnosis and / or prognosis of a disease with sensorineural hearing loss.
The group is looking for the following collaboration:
-License agreement, in the framework of authorizing the interested parties to use the technology.
-Technical cooperation agreement, to collaborate with other research teams, companies or foundations to improve the technologies.
- Two allelic variants located in specific genomic coordinates have a high frequency (0.29 and 0.42) in the general population and in patients and are very useful for establishing the prognosis with high diagnostic yield.
- The polymorphisms allow obtaining useful information in the diagnosis and / or prognosis of a sensorineural hearing loss disease.
-The identification of a more aggressive form of the disease may determine an alternative therapeutic approach that includes intratympanic drug therapy and surgery.
PCT patent application
The research group aims to formalize a technology transfer process with entities interested in the implementation of the solution, through a license agreement.
If there are some entities, such as R&D centres, technology centres or specialized companies, interested in collaborating and developing further aspects of the solution, a technical cooperation agreement could be envisaged.
The research group already sell the technology in Spain and now they want to expand abroad